<DOC>
	<DOC>NCT00461708</DOC>
	<brief_summary>This single arm study will evaluate the relationship between the skin toxicity of Tarceva in combination with gemcitabine, and survival, in patients with advanced and/or metastatic pancreatic cancer. All patients will receive gemcitabine 100mg/m2 i.v. weekly; Tarceva will be administered 100mg po per day. The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; locally advanced and/or metastatic pancreatic cancer (stage III or IV); Karnofsky performance Status of &gt;=60%. local(stage IA to IIB) pancreatic cancer; &lt;=6 months since last adjuvant chemotherapy; previous systemic therapy for metastatic pancreatic cancer; other primary tumor within last 5 years (except for adequately treated cancer in situ of cervix, or basal cell skin cancer); clinically significant cardiovascular disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>